Clinical Report: Assessing the Necessity of Transurethral Resection in Cases of Suspected Primary Bladder Cancer

Overview

This study evaluates the malignancy detection rate in patients undergoing elective transurethral resection of bladder tumor (TURBT) for suspected bladder cancer (BC). Findings suggest that a significant proportion of patients may not require TURBT, highlighting the need for improved preoperative diagnostic criteria.

Background

Bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC), presents with diverse clinical symptoms and cystoscopic appearances, complicating diagnosis. The standard approach for diagnosis and treatment, TURBT, may lead to unnecessary procedures in patients with benign findings. Given the strain on healthcare resources and the psychological impact on patients, it is crucial to identify factors that could help avoid unnecessary TURBT.

Data Highlights

Key Findings

• 35% of patients undergoing TURBT had no malignancy detected.
• Interobserver congruence on preoperative and TURBT findings was 80.6%.
• Significant predictors for malignancy included papillary findings (OR = 5.6), age (OR = 1.057), and tumor size (OR = 1.9).
• The study emphasizes the need for selective criteria for TURBT to avoid unnecessary procedures.
• Healthcare systems face challenges in managing TURBT due to resource constraints and increasing patient loads.

Clinical Implications

Clinicians should consider the potential for benign findings in patients referred for TURBT and evaluate preoperative factors that may indicate a lower likelihood of malignancy. Optimizing diagnostic protocols could reduce unnecessary surgical interventions and improve patient outcomes.

Conclusion

The findings suggest that not all patients with suspected bladder cancer require immediate TURBT, advocating for a more selective approach to diagnosis and treatment. This could alleviate healthcare burdens and enhance patient care.

Related Resources & Content

1. Revised Reporting Guidelines for Bladder Cancer Pathology: Insights on Biopsies, Transurethral Resections, and Radical Cystectomies, 2021 -- Springer
2. Insights from the 2018 Stockholm Consultation on the Diagnosis of Upper Tract Urothelial Carcinoma, 2019 -- Springer
3. The Role of pT3 Substaging in Lymph Node-Negative Urothelial Bladder Carcinoma: Do Pathological Factors Contribute to Prognostic Stratification?, 2021 -- Springer
4. Exploring Urothelial Carcinomas of the Upper Urinary Tract: A Decade of Experience from a Single Institution, 2016 -- Springer
5. EAU Guidelines on Non-muscle Invasive Bladder Cancer, 2025 -- EAU
6. En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis
7. Implementing VIRADS score for image-guided assessment of muscle invasiveness in bladder cancer pre-TURBT: An updated meta-analysis
8. https://d56bochluxqnz.cloudfront.net/documents/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2025.pdf